ImpedanCELL: A core facility to screen and evaluate antiviral compounds against equine viruses and a new approach to sero-neutralisation - Normandie Université
Communication Dans Un Congrès Année : 2024

ImpedanCELL: A core facility to screen and evaluate antiviral compounds against equine viruses and a new approach to sero-neutralisation

Résumé

Background: ImpedanCELL (labelled IBiSA, national recognition by the major research institutions in France) is an innovative and original core facility for the study of real-time high throughput cellular activity using impedance measurement (xCELLigence technology) and realtime cellular imaging. It is located in the equine research department of LABEO, Saint-Contest, for infectious disease applications (biosafety level 2) and in Comprehensive Cancer Center F. Baclesse, Caen, for all non- infectious applications. The core facility is equipped with cutting-edge technologies based on xCELLigence Real-Time Cell Analysis (RTCA) and live-cell imaging devices (Incucyte S3) both allowing the study of proliferation, cell death, adhesion, migration and invasion in various domains including virology, bacteriology, immunology, toxicology, oncology. Objectives: To illustrate different applications of the ImpedanCELL platform for (1) the screening and identification of antiviral compounds against equine viruses and (2) development of real-time neutralisation test, a new serological approach. Study design: In vitro experiments. Methods: A high-throughput screening of 2891 compounds was performed against Varicellovirus equidalpha1 (EHV-1) [1] and 42 compounds against EHV-4.[2] Efficacy of the identified compounds was confirmed by qPCR and microscopy observation. The technology has also been tested to measure antibody levels quantitatively (RTNA). Results: Six compounds were identified for their antiviral potency on different cell lines (E. Derm, RK13 and EEK cells) against alpha-EHV including EHV-1 variants (ORF30 2254 A/G/C) and EHV-4. A strong correlation was observed between RTNA and seroneutralisation test for EHV-1 and equine influenza virus (EIV). Main limitations: The number of samples tested for RTNA. Conclusions: This work has shown that impedance measurement is very useful for screening antiviral compounds and quantified serological responses for different equine viruses (alpha-EHV, EIV). The core facility is open to collaborations and services for both academic and industrial partners and offers theoretical and practical courses. Ethical animal research: Not applicable. Informed consent: Not applicable. Competing interests: None declared. Funding: CENTAURE European project co-financed by the Conseil Régional de Normandie, European Union within the framework of the ERDF-SSE operational programme 2014–2020 References: [1] Thieulent C, Hue ES, Sutton G, Fortier C, Dallemagne P, Zientara S, Munier-Lehmann H, Hans A, Paillot R, Vidalain P-O, Pronost S. Identification of antiviral compounds against equid herpesvirus-1 using real-time cell assay screening: Efficacy of decitabine and valganciclovir alone or in combination. Antiviral Res. 2020;183:104931. doi:10.1016/j.antiviral.2020.104931. [2] Normand et al., Viruses. 2024;16(5):746. doi: https://doi.org/10.3390/v16050746
Fichier non déposé

Dates et versions

hal-04723757 , version 1 (07-10-2024)

Identifiants

Citer

Erika Hue, Camille Normand, Côme Thieulent, Gabrielle Sutton, Flora Carnet, et al.. ImpedanCELL: A core facility to screen and evaluate antiviral compounds against equine viruses and a new approach to sero-neutralisation. 12th International Equine Infectious Diseases Conference, Sep 2024, Deauville, France. pp.70 (n°108), ⟨10.1111/evj.14215⟩. ⟨hal-04723757⟩
45 Consultations
0 Téléchargements

Altmetric

Partager

More